(Reuters) – Eli Lilly and Co said it would stop the development of its drug to treat the autoimmune disorder lupus, after it was found to be not effective enough in late-stage trials. While Lilly’s shares hardly budged on the news, the ADRs of Israel-based XTL…
Source:Eli Lilly stops development of lupus drug; XTL shares soar
Thursday, October 2, 2014
Eli Lilly stops development of lupus drug; XTL shares soar
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment